• Consensus Rating: Buy
  • Consensus Price Target: $12.00
  • Forecasted Upside: -11.44%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$13.55
▲ +0.24 (1.80%)

This chart shows the closing price for BVS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Bioventus Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BVS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BVS

Analyst Price Target is $12.00
▼ -11.44% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for Bioventus in the last 3 months. The average price target is $12.00, with a high forecast of $17.00 and a low forecast of $7.00. The average price target represents a -11.44% upside from the last price of $13.55.

This chart shows the closing price for BVS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Bioventus. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/9/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/7/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/5/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/3/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/3/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/1/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/30/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/30/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/27/2024Craig HallumBoost TargetBuy ➝ Buy$12.00 ➝ $17.00
8/13/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$8.00 ➝ $12.00
8/7/2024Craig HallumBoost TargetBuy ➝ Buy$9.00 ➝ $12.00
5/8/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$7.00 ➝ $8.00
3/13/2024Craig HallumBoost TargetBuy ➝ Buy$6.00 ➝ $9.00
12/7/2023Canaccord Genuity GroupUpgradeHold ➝ Buy$3.66 ➝ $7.00
12/7/2023Canaccord Genuity GroupUpgradeHold ➝ Buy$7.00
8/9/2023Craig HallumUpgradeHold ➝ Buy$4.00 ➝ $6.00
4/3/2023Craig HallumLower TargetHold$10.00 ➝ $5.00
11/22/2022Craig HallumDowngradeBuy ➝ Hold$10.00
11/10/2022Morgan StanleyLower TargetOverweight$11.00 ➝ $5.00
11/9/2022Craig HallumLower Target$25.00 ➝ $10.00
11/9/2022Canaccord Genuity GroupDowngradeBuy ➝ Hold$18.00 ➝ $6.00
11/9/2022JPMorgan Chase & Co.DowngradeOverweight ➝ Underweight
10/11/2022Morgan StanleyLower TargetOverweight$12.00 ➝ $11.00
8/12/2022Morgan StanleyBoost TargetOverweight$11.00 ➝ $12.00
3/21/2022The Goldman Sachs GroupLower TargetNeutral$19.00 ➝ $17.00
3/15/2022Craig HallumInitiated CoverageBuy$30.00
3/11/2022Morgan StanleyLower TargetOverweight$20.00 ➝ $18.00
11/15/2021Morgan StanleyInitiated CoverageOverweight$20.00
11/9/2021JPMorgan Chase & Co.Initiated CoverageOverweight$25.00
7/1/2021The Goldman Sachs GroupDowngradeBuy ➝ Neutral$20.00 ➝ $19.00
4/19/2021Morgan StanleyBoost TargetOverweight$18.00 ➝ $19.00
3/8/2021JPMorgan Chase & Co.Initiated CoverageOverweight$17.00
3/8/2021Morgan StanleyInitiated CoverageOverweight$18.00
3/8/2021The Goldman Sachs GroupInitiated CoverageBuy$19.00
(Data available from 10/30/2019 forward)

News Sentiment Rating

0.74 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/3/2024
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/3/2024
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/2/2024
  • 5 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/2/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/1/2024
  • 8 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/31/2024
  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/30/2024
  • 5 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/30/2024

Current Sentiment

  • 5 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Bioventus logo
Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $13.55
Low: $13.22
High: $13.72

50 Day Range

MA: $11.35
Low: $9.12
High: $13.35

52 Week Range

Now: $13.55
Low: $3.36
High: $13.72

Volume

158,603 shs

Average Volume

387,671 shs

Market Capitalization

$1.10 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.9

Frequently Asked Questions

What sell-side analysts currently cover shares of Bioventus?

The following Wall Street sell-side analysts have issued reports on Bioventus in the last twelve months: Canaccord Genuity Group Inc., and Craig Hallum.
View the latest analyst ratings for BVS.

What is the current price target for Bioventus?

3 Wall Street analysts have set twelve-month price targets for Bioventus in the last year. Their average twelve-month price target is $12.00, suggesting a possible downside of 11.4%. Craig Hallum has the highest price target set, predicting BVS will reach $17.00 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of $7.00 for Bioventus in the next year.
View the latest price targets for BVS.

What is the current consensus analyst rating for Bioventus?

Bioventus currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BVS will outperform the market and that investors should add to their positions of Bioventus.
View the latest ratings for BVS.

What other companies compete with Bioventus?

How do I contact Bioventus' investor relations team?

Bioventus' physical mailing address is 4721 EMPEROR BOULEVARD SUITE 100, DURHAM NC, 27703. The company's listed phone number is 919-474-6700 and its investor relations email address is [email protected]. The official website for Bioventus is www.bioventus.com. Learn More about contacing Bioventus investor relations.